Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25606317 | 1.00 | NR1H2 (0.41) | NR1H2NR1H3EIF2AK4MAP4K4HTRA1 | |
| SCHEMBL29252894 | 1.00 | NR1H2 (0.41) | NR1H2NR1H3EIF2AK4MAP4K4HTRA1 | |
| SCHEMBL25606236 | 0.91 | NR1H3 (0.40) | NR1H2NR1H3EIF2AK4MAP4K4USP30 | |
| SCHEMBL25221694 | 0.91 | NR1H3 (0.40) | NR1H2NR1H3EIF2AK4MAP4K4USP30 | |
| SCHEMBL29252847 | 0.85 | GPR119 (0.45) | NR1H2NR1H3EIF2AK4MAP4K4HTRA1 | |
| SCHEMBL25263043 | 0.85 | GPR119 (0.45) | NR1H2NR1H3EIF2AK4MAP4K4HTRA1 | |
| SCHEMBL38663567 | 0.80 | NR1H2 (0.48) | NR1H2NR1H3EIF2AK4MAP4K4USP30 | |
| SCHEMBL25216734 | 0.79 | NR1H2 (0.49) | NR1H2NR1H3MAP4K4USP30LMNA | |
| SCHEMBL25606205 | 0.77 | NR1H2 (0.63) | NR1H2NR1H3MAP4K4USP30LMNA | |
| SCHEMBL30982325 | 0.77 | ITGB3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| EP-4405334-A1 | SORTILIN INHIBITORS | Sortina Pharma AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | NR1H2 1056/4885NR1H3 1185/4885EIF2AK4 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.